Breaking the Silence: How Female Cancer Disrupts Daily Life – Insights from South Korea’s Expert Panel
In South Korea, a groundbreaking new therapy for ovarian cancer—approved but underfunded—threatens patient survival rates due to outdated reimbursement systems. The drug, a PARP inhibitor (a class of targeted therapy ... Read More